Search

Complete abstract information will be provided to the CMSC Annual Meeting attendees on May 28, 2023.

CMSC Abstracts Search Form (Titles and Authors only)

Search Accepted Abstracts
Sending

Search Results

Year ID Type Category Title Authors
2019 DXT29 Poster Disease Modifying Therapy

Safety and Efficacy of Ocrelizumab in Multiple Sclerosis (MS) Patients

Claudia Chaves, MD, Daniel Gans, undergraduate student, Jessica Vecchia, RN, MSN, Catia Melo, SC and Ann Camac, MD, Neurology, Lahey Clinic, Lexington, MA

2019 DXT30 Poster Disease Modifying Therapy

The Occurrence of Infusion-Related Reactions Among Patients with Multiple Sclerosis Undergoing Treatment with Ocrevus (Ocrelizumab) in a Community Setting Receiving a Standard Pre-Infusion Protocol.

Hollis O’Nell-Meyer, BA1, Jennifer A. Ruiz, DPT2, Elizabeth S Gromisch, PhD2,3, Lindsay Neto, MPH2 and Peter Wade, MD2, (1)Frank H. Netter Medical School at Quinnipiac University, North Haven, CT, (2)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (3)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT

2019 DXT31 Poster Disease Modifying Therapy

Clarity Extension: Long-Term Efficacy of Cladribine Tablets in Patients with High Disease Activity at Baseline Following Switch to Placebo

Patrick Vermersch, PhD, University of Lille, Lille, France, Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, Queen Mary University of London, London, United Kingdom, Per Soelberg Soerensen, MD, Department of Neurology, University of Copenhagen, Copenhagen, Denmark, Birgit Keller, Diplom, Merck KGaA, Darmstadt, Germany and Dominic Jack, PhD, Merck Serono Ltd, Middlesex, United Kingdom

2019 DXT32 Poster Disease Modifying Therapy

Relapses, Healthcare Resource Use, and Costs Among Patients with Multiple Sclerosis Taking Maintenance (once- or twice-daily) Oral Disease Modifying Drugs and Experiencing Lapses in Therapy

Jacqueline A. Nicholas, MD, MPH, OhioHealth Multiple Sclerosis Center, Columbus, OH, Natalie C Edwards, MSc, Health Services Consulting Corporation, Boxborough, MA, Anna Dellarole, PhD, Fair Dynamics Consulting, Milan, Italy, Danielle E Harlow, PhD, US Medical Affairs – Neurology & Immunology, EMD Serono, Inc., Rockland, MA and Amy L Phillips, PharmD, Data Analytics & Value Assessment, EMD Serono, Inc., Rockland, MA

2019 DXT33 Poster Disease Modifying Therapy

Comorbidity and Concomitant Medication Use Among Patients with Multiple Sclerosis Newly Initiating Disease-Modifying Drugs

Jacqueline Nicholas, MD, MPH, Ohio Multiple Sclerosis Center, Columbus, OH, Natalie C Edwards, MSc, Health Services Consulting Corporation, Boxborough, MA, Danielle E Harlow, PhD, US Medical Affairs – Neurology & Immunology, EMD Serono, Inc., Rockland, MA and Amy L Phillips, PharmD, Data Analytics & Value Assessment, EMD Serono, Inc., Rockland, MA

2019 DXT34 Poster Disease Modifying Therapy

Lapses in Treatment and Treatment Discontinuation Among Patients with Multiple Sclerosis Newly Initiating Once- or Twice-Daily Oral Disease-Modifying Drugs

Jacqueline Nicholas, MD, MPH, Ohio Multiple Sclerosis Center, Columbus, OH, Natalie C Edwards, MSc, Health Services Consulting Corporation, Boxborough, MA, Danielle E Harlow, PhD, US Medical Affairs – Neurology & Immunology, EMD Serono, Inc., Rockland, MA and Amy L Phillips, PharmD, Data Analytics & Value Assessment, EMD Serono, Inc., Rockland, MA

2019 DXT35 Poster Disease Modifying Therapy

Feasibility of Classic MS Assessing Long-Term Efficacy for Patients with Multiple Sclerosis Treated with Cladribine Tablets in the Phase 3 Trials

Mark S Freedman, MSc, MD, FAAN, FRCPC, THe University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada, Alexey N Boyko, MD, Pirogov Russian National Research University & Demyelinating Diseases Center, Usupov Hospital, Moscow, Russia, Jorge Correale, MD, Department of Neurology, FLENI, Buenos Aires, Argentina, Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, Queen Mary University of London, London, United Kingdom, Thomas Leist, MD, Thomas Jefferson University, Philadelphia, PA, Xavier Montalban, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain; Division of Neurology, University of Toronto, Toronto, ON, Canada, Kottil Rammohan, MD, University of Miami, Miami, FL, Bassem Yamout, MD, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon, Pedro Testi, BSc, Merck KGaA, Darmstadt, Germany and Kristin Gabriel, DO, MPH, EMD Serono Research & Development Institute Inc., Billerica, MA

2019 DXT36 Poster Disease Modifying Therapy

A Retrospective Claims Analysis of Multiple Sclerosis Relapse Rates and Economic Outcomes with Generic Glatiramer Acetate Using US Health Plan Data

Benjamin Greenberg, MD, MHS, Department of Neurology, UT Southwestern, Dallas, TX, Michael Grabner, PhD, HealthCore, Inc., Wilmington, DE, Xian Zhang, PhD, HealthCore Inc., Wilmington, DE, Sanjeev Balu, PhD, MBA, B.Pharmacy, Sandoz, Inc, Princeton, NJ, Steve Hall, Pharm.D., Sandoz, Inc., Princeton, NJ and Daniel Kantor, MD, FAAN, FANA, Florida Atlantic University, Boca Raton, FL

2019 DXT37 Poster Disease Modifying Therapy

Long-Term Clinical Outcomes in Patients with CIS Treated with Interferon Beta-1b: Health-Related Quality of Life in Benefit 15

Ludwig Kappos, MD, University Hospital Basel, University of Basel, Basel, Switzerland, Mark S Freedman, MSc, MD, FAAN, FRCPC, THe University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada, Gilles Edan, MD, CHU Hopital Pontchaillou, Rennes, France, Hans-Peter Hartung, MD, Department of Neurology, UKD, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, Xavier Montalban, MD, PhD, Hospital Universitari Vall d’Hebron, Multiple Sclerosis Center of Catalonia (Cemcat), Barcelona, Spain; University of Toronto, St. Michael’s Hospital, Toronto, Canada, Frederik Barkhof, MD, PhD, VU University Medical Center, Amsterdam, Netherlands; Institutes of Neurology and Healthcare Engineering, UCL, London, United Kingdom, Ralf Koelbach, MSc, PAREXEL International, Berlin, Germany and Eva-Maria Wicklein, MD, Bayer Pharma AG, Berlin, Germany

2019 DXT38 Poster Disease Modifying Therapy

Clinical and Economic Burden of Non-Adherence to Oral Disease-Modifying Drugs in Patients with Multiple Sclerosis: A Cost-Consequence Model

Jacqueline Nicholas, MD, MPH, Ohio Multiple Sclerosis Center, Columbus, OH, Natalie C Edwards, MSc, Health Services Consulting Corporation, Boxborough, MA, Anna Dellarole, PhD, Fair Dynamics Consulting, Milan, Italy, Danielle E Harlow, PhD, US Medical Affairs – Neurology & Immunology, EMD Serono, Inc., Rockland, MA and Amy L Phillips, PharmD, Data Analytics & Value Assessment, EMD Serono, Inc., Rockland, MA

2019 DXT39 Poster Disease Modifying Therapy

A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-Beta-1a in Multiple Sclerosis.

Theodore R Brown, MD, MPH, MS Center at Evergreen Health, Evergreen Health, Kirkland WA, WA and Virginia I Simnad, MD, MS, MS Center at Evergreen Health, Evergreen Health, Kirkland, WA

2019 DXT40 Poster Disease Modifying Therapy

Outcomes of Dimethy Fumarate Discontinuation Rates from a Pharmacist-Led Titration Protocol

Lauren Long, Pharm.D. and Ryan Fuller, Pharm.D., Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA

2019 DXT41 Poster Disease Modifying Therapy

Tolerability of Diroximel Fumarate in Patients with Relapsing-Remitting MS: Analysis of Gastrointestinal and Flushing Events in the Phase 3 Evolve-MS-1 Study

Sibyl Wray, MD1, Samuel F Hunter, MD, PhD2, Richard Leigh-Pemberton, MD3, Ilda Bidollari, MD, MBA3, Hailu Chen, PhD4, Lili Yang, PhD4, Catherine Miller, PharmD, MPH4 and Jerome Hanna, PhD5, (1)Hope Neurology MS Center, Knoxville, TN, (2)Advanced Neurosciences Institute, Franklin, TN, (3)Alkermes Inc., Waltham, MA, (4)Biogen, Cambridge, MA, (5)Biogen, Maidenhead, United Kingdom

2019 DXT42 Poster Disease Modifying Therapy

Efficacy of Diroximel Fumarate in Relapsing-Remitting MS Patients Who Are Newly Diagnosed or Previously Treated with Interferons or Glatiramer Acetate

Mark Gudesblatt, MD1, Sibyl Wray, MD2, Catherine Miller, PharmD, MPH3, Jerome Hanna, PhD4, Maria Lopez-Bresnahan, MD5, Boris Kandinov, PhD5, Hailu Chen, PhD3, Lili Yang, PhD3 and Richard Leigh-Pemberton, MD5, (1)South Shore Neurologic Associates, Patchogue, NY, (2)Hope Neurology MS Center, Knoxville, TN, (3)Biogen, Cambridge, MA, (4)Biogen, Maidenhead, United Kingdom, (5)Alkermes Inc., Waltham, MA

2019 DXT43 Poster Disease Modifying Therapy

Demographic and Clinical Characteristics of Patients Treated with Ocrelizumab in the United States

Tu My To, PhD, MPH1, Erru Yang, MS1, Eddie Jones, BA2, Damian Fiore, Pharm.D1 and Natalie Engmann, PhD, MSc1, (1)Genentech, Inc., South San Francisco, CA, (2)Adelphi Real World, Cheshire, United Kingdom

2019 DXT44 Poster Disease Modifying Therapy

Multiple Sclerosis Disease Modifying Therapy Prescribing Practices at an Academic Medical Center

Casey V Farin, MD1, Suma Shah, MD1, Jenelle M. Hall, PharmD2, Fletcher L Hartsell III, MD MPH1 and Christopher Eckstein, MD1, (1)Neurology, Duke University, Durham, NC, (2)Duke University, Durham, NC

2019 DXT45 Poster Disease Modifying Therapy

Evaluation of Beliefs Related to Discontinuation of Disease Modifying Therapies in a Cohort of Patients with Clinical Stability for More Than 10 Years

Mirela Cerghet, MD, PhD1,2, Lonni Schultz, PhD3, Helena Bulka, DO1 and Stanton Elias, MD1, (1)Neurology, Henry Ford Hospital, Detroit, MI, (2)School of Medicine, Wayne State University, Detroit, MI, (3)Public Health Science, Henry Ford Health System, Detroit, MI

2019 DXT46 Poster Disease Modifying Therapy

Measurement of Anti-Glatiramer Acetate (GA) Antibodies in the Serum of RRMS Subjects Treated with GA Depot for 24 Months

Shlomo Flechter, MD1, Ariel Miller, MD, PhD2,3, Laura Popper, MD4, Nadav Bleich Kimelman, DMD, PhD4, Shai Rubnov, PhD4, Uri Danon, MBA, B.Sc4, Ehud Marom, B.Sc.4, Ron Milo, MD5,6, Joab Chapman, MD, PhD7,8, Alla Shifrin, MD9, Ronit Gilad, MD10, Chen Hoffmann, MD11, Dimitrios Karussis, MD, PhD12, Talma Brenner, PhD13, Tamir Ben-Hur, MD, PhD14 and Arnon Karni, MD, PhD8,15, (1)Multiple Sclerosis Clinical Research and Therapy Service, Department of Neurology, Assaf Harofeh Medical Center, Zerifin, Israel, (2)Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, (3)Multiple Sclerosis & Brain Research Center, Carmel Medical Center, Haifa, Israel, (4)Mapi Pharma Ltd, Ness Ziona, Israel, (5)Department of Neurology, Barzilai University Medical Center, Ashkelon, Israel, (6)Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel, (7)Department of Neurology, Sheba Medical Center, Ramat Gan, Israel, (8)Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, (9)Department of Neurology, Rambam Medical Center, Haifa, Israel, (10)Department of Neurology, Kaplan Medical Center, Rehovot, Israel, (11)Diagnostic and Interventional Imaging, Sheba Medical Center, Ramat Gan, Israel, (12)Unit of Neuroimmunology-MS Center, Hadassah Medical Center, Ein Kerem, Jerusalem, Israel, (13)Laboratory of Neuroimmunology, Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, (14)Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, (15)Neuroimmunology Clinic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

2019 DXT47 Poster Disease Modifying Therapy

A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with Multiple Sclerosis

Scott D. Newsome, DO1, Thomas Shoemaker, MD2, Pavan Bhargava, MD1, Sarah Snoops, RN1, Fan Tian, MSE1, Kathryn C Fitzgerald, Sc.M., Sc.D.1, David Cooper, MD3, Jennifer Mammen, MD, MPhil, PhD3, Ellen M Mowry, MD, MCR1 and Peter A Calabresi, MD1, (1)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (2)Neurology, Rush University Medical Center, Chicago, IL, (3)Endocrinology, Johns Hopkins University School of Medicine, Baltimore, MD

2019 DXT48 Poster Disease Modifying Therapy

Lymphocytic and Immunoglobulins Depletion in Ocrelizumab Treated Multiple Sclerosis (MS) Patients

Claudia Chaves, MD, Daniel Gans, undergraduate student, Catia Melo, SC, Jessica Vecchia, RN, MSN and Ann Camac, MD, Neurology, Lahey Clinic, Lexington, MA

2019 DXT49 Poster Disease Modifying Therapy

Harmonization of Neda: Re-Analysis of Neda Data from Phase III Infusion Monoclonal Antibody Trials

John F Kramer, PA-C, Neurology, St Thomas Medical Partners, Nashville, TN and Adil Javed, MD, Neurology, The University of Chicago, Chicago, IL

2019 DXT50 Poster Disease Modifying Therapy

Investigation of Infusion Related Reactions in Patients Treated with Ocrelizumab at an Academic Center: A Retrospective Analysis (The InfuseOcreliz Study)

Natalya Belotserkovskaya, MD, Neurology and Rehabilitation, University of Cincinnati, Cincinnati, OH

2019 DXT51 Poster Disease Modifying Therapy

Evaluation of Shorter Infusion Times with Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis

Timothy Vollmer, MD1, Enrique Alvarez, MD1, Kavita Nair, PhD1, Jeffrey A Cohen, MD2, Aaron Boster, MD3, Ashish Pradhan, MD4, Bruno Musch, MD, PhD4, Xiaoye Ma, PhD4, Jinglan Pei, PhD4, Ming Yang, PhD4, Brandon Moss, MD2, Bianca Weinstock-Guttman, MD5 and Robert Bermel, MD2, (1)University of Colorado Anschutz Medical Campus, Aurora, CO, (2)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, (3)OhioHealth Multiple Sclerosis Center, Columbus, OH, (4)Genentech, Inc., South San Francisco, CA, (5)University at Buffalo, Buffalo, NY

2019 DXT52 Poster Disease Modifying Therapy

Assessing the Safety and Tolerability of Conversion to Siponimod in Patients with Relapsing Forms of Multiple Sclerosis: Design of the Exchange Study

Enrique Alvarez, MD, PhD1, Amit Bar-Or, MD2,3, Guy J Buckle, MD4, Stanley L Cohan, MD, PhD5, Bruce A C Cree, MD, PhD, MAS6, Yang Mao-Draayer, MD, PhD7, Micheline McCarthy, MD, PhD8, Aaron E Miller, MD9, Bianca Weinstock-Guttman, MD10, Nina Jaitly, MD, MPH11, Linda-Ali Cruz, MD11, Scott Kolodny, MD11, Xiangyi Meng, PhD11, Davorka Tomic, PhD12 and Wendy Su, PhD11, (1)Department of Neurology, University of Colorado School of Medicine, Aurora, CO, (2)Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, (3)Center for Neuroinflammation and Experimental Therapeutics, and Multiple Sclerosis Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (4)Shepherd Center, Atlanta, GA, (5)Providence Multiple Sclerosis Center, The Providence Brain Institute, Portland, OR, (6)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, (7)University of Michigan, Ann Arbor, MI, (8)Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, (9)Icahn School of Medicine at Mount Sinai, New York, NY, (10)University at Buffalo, Buffalo, NY, (11)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (12)Novartis Pharma AG, Basel, Switzerland

2019 DXT53 Poster Disease Modifying Therapy

Efficacy of Cladribine Tablets 3.5mg/Kg in Patients with Relapsing Multiple Sclerosis Aged Above and below 45 Years; Clarity and Clarity Extension

2019 DXT54 Poster Disease Modifying Therapy

Balancing Risk and Disease Control during Pregnancy in MS: Impact of Medical Education on Knowledge and Competence Among Neurologists and Primary Care Physicans

Thomas Finnegan, PhD, Catherine Murray, MA and John Maeglin, BA, Medscape Education, New York, NY

2019 DXT55 Poster Disease Modifying Therapy

Severity and Frequency of Relapses in Patients with Relapsing-Remitting MS Treated with Cladribine Tablets in Clarity and Placebo in Clarity Extension

Sven Schippling, MD, Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich and University of Zurich, Zurich, Switzerland, Maria Pia Sormani, PhD, Biostatistics Unit, University of Genoa, Genoa, Italy, Nicola De Stefano, MD, Department of Neurological and Behavioural Sciences, University of Siena, Siena, Italy, Gavin Giovannoni, MD, Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom, Fernando Dangond, MD, Global Clinical Development Center, EMD Serono, Inc., Billerica, MA, Andrew Galazka, MD, Merck, Aubonne, Switzerland, Birgit Keller, Diplom, Merck KGaA, Darmstadt, Germany and Nektaria Alexandri, MD, MSc, Neurology and Immunology, Merck KGaA, Darmstadt, Germany

2019 DXT56 Poster Disease Modifying Therapy

Relapse Outcomes in Clarity EXT Patients Treated with Cladribine Tablets or Placebo Were Comparable Regardless of the between-Trial Bridging Intervals

Kottil Rammohan, MD1, Doris Damian, PhD2, Yann Hyvert, PhD3, Fernando Dangond, MD4, Lori Lebson, PhD2 and Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath5, (1)Ohio State University Hospital, Columbus, OH, (2)EMD Serono, Inc., Billerica, MA, (3)EMD Serono, Inc., Rockland, MA, (4)Global Clinical Development Center, EMD Serono, Inc., Billerica, MA, (5)Queen Mary University of London, London, United Kingdom

2019 DXT57 Poster Disease Modifying Therapy

Network Meta-Analysis of Cladribine Tablets Versus Alternative Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Tolerability and Quality-of-Life Outcomes

Barry A Singer, MD1, Kiren Kresa-Reahl, MD2, Gerard Harty, MSc3, Daniel Jones, PhD4, Gary Cutter, PhD5 and Schiffon L Wong, PhD3, (1)MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, (2)Providence MS Center, Portland, OR, (3)EMD Serono, Inc., Billerica, MA, (4)EMD Serono, Inc., Rockland, MA, (5)Department of Biostatistics, UAB School of Public Health, Birmingham, AL

2019 DXT58 Poster Disease Modifying Therapy

Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis

Stuart Cook, MD1, Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath2, Thomas Leist, MD3, Sana Syed, MPH4, Axel Nolting, MD5, Doris Damian, PhD4 and Regina Schick, MD5, (1)Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ, (2)Queen Mary University of London, London, United Kingdom, (3)Thomas Jefferson University, Philadelphia, PA, (4)EMD Serono, Inc., Billerica, MA, (5)Merck KGaA, Darmstadt, Germany

2019 DXT59 Poster Disease Modifying Therapy

Is Lipid Metabolism the Missing Link in Brain Diseases?

John D Nieland, PhD, Associate Prof., Department of Health Science and Technology, Aalborg University, Aalborg, Denmark

2019 DXT60 Poster Disease Modifying Therapy

Timing and Incidence of Infusion-Related Reactions Associated with Natalizumab Treatment in Patients with Multiple Sclerosis

Lily Lee, PhD1, Rachna Kasliwal, MPH2, Yogi Patel, PhD3, Jonathan Smith, MSc2, Christophe Hotermans, MD, PhD1, Denise Campagnolo, MD1 and Thos Cochrane, MD, MBA1, (1)Biogen, Cambridge, MA, (2)Biogen, Maidenhead, United Kingdom, (3)Biogen at the time of this work, Maidenhead, United Kingdom

2019 DXT61 Poster Disease Modifying Therapy

Dynamics of Pseudoatrophy in Relapsing-Remitting MS Patients Treated with Interferon beta-1a As Assessed By Monthly Brain MRI

Marco Battaglini, PhD1, Antonio Giorgio, MD1, Ludovico Luchetti, MS1, Maria Laura Stromillo, MD1, Andrea Visconti, MD2, Maria Pia Sormani, PhD3 and Nicola De Stefano, MD1, (1)Department of Medicine, Surgery, and Neurosciences, University of Siena, Siena, Italy, (2)Medical Affairs Department, Merck Serono, Rome, Italy, (3)Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

2019 DXT62 Poster Disease Modifying Therapy

Initiation of Higher-Efficacy Disease-Modifying Therapy and Depressive Symptom Evolution in Patients with Multiple Sclerosis

Youkyung S Roh, BA1, Ellen M Mowry, MD, MCR2 and Kathryn C Fitzgerald, Sc.M., Sc.D.2, (1)Johns Hopkins University School of Medicine, Baltimore, MD, (2)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD

2019 DXT63 Poster Disease Modifying Therapy

Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Two Data

Hannah M Geils, B.S., Joshua D Katz, M.D., Ellen S Lathi, MD and India C Stribling, B.S., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA

2019 DXT64 Poster Disease Modifying Therapy

Phase 2 Open-Label, Multicenter Study of Repeated Intrathecal Administration of Autologous MSC-Ntf Cells in Progressive Multiple Sclerosis

Ralph Kern, MD, MHSc, Clinical, BrainStorm Cell Therapeutics, New York, NY, Jeffrey A Cohen, MD, Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, Tanuja Chitnis, MD, Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Daniel Pelletier, MD, Keck School of Medicine of University of Southern California, Los Angeles, CA, Fred Lublin, MD, Icahn School of Medicine at Mount Sinai, New York, NY, Christopher B. Lock, MD, PhD, Stanford School of Medicine, Palo Alto, CA and Yael Gothelf, Ph.D., BrainStorm Cell Therapeutics, Petach Tikva, Isreal and New York, NY

2019 DXT65 Poster Disease Modifying Therapy

Advance: Peginterferon Beta-1a Patients 50 Years and Older Age Subgroup Analysis and Effect on Clinical and Radiological Outcomes

Stephen Newman, MD1, Yang Mao-Draayer, MD, PhD2, Karen Blitz, DO3, Ray Su, PhD4, Jason P Mendoza, PhD4 and Robin Avila-Carey, PhD4, (1)Neurological Associates, Plainview, NY, (2)Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, (3)Island Neurology Care, Massapequa, NY, (4)Biogen, Cambridge, MA

2019 DXT66 Poster Disease Modifying Therapy

Cumulative Data from the European Interferon Beta Pregnancy Registry

2019 DXT67 Poster Disease Modifying Therapy

Acapella: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients

Hannah M Geils, B.S., India C Stribling, B.S., Joshua D Katz, M.D. and Ellen S Lathi, MD, The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA

2019 DXT68 Poster Disease Modifying Therapy

Real-World Infection Rates and Lymphocyte Counts in Patients ?50 Years with Relapsing-Remitting MS Treated with Subcutaneous Interferon beta-1a or Dimethyl Fumarate

Brooke Hayward, SM, MBA1, Sarah Cardoso, MD2, Megan Grosso, PA-C, DPT, PT1, Soudeh Ansari, PhD3 and Salvatore Napoli, MD2, (1)EMD Serono, Inc., Rockland, MA, (2)Neurology Center of New England, Foxboro, MA, (3)Prometrika LLC, Cambridge, MA